NCT04257162: HER2-PREDICT: Translational Study of Tumor Samples From DS8201-A-U301 and DS8201-A-U302 Trials.

NCT04257162
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: 

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have participated in either NCT03529110 or NCT03523585
Exclusions: Patients with spinal cord compression or active central nervous system (CNS) metastases, defined as untreated and symptomatic, or requiring therapy – see trial for details
https://ClinicalTrials.gov/show/NCT04257162

Comments are closed.

Up ↑